13:29 , Apr 5, 2019 |  BioCentury  |  Product Development

Reaching addiction patients where they’re at

Coming at the opioid crisis from two different angles, NIH’s National Institute on Drug Abuse and Alkermes plc have concluded that ending the epidemic will mean developing ways of getting medication to patients who fall...
22:06 , Apr 28, 2017 |  BioCentury  |  Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
19:49 , Feb 17, 2017 |  BC Week In Review  |  Company News

Gilead, Amygdala deal

Amygdala acquired GS-6637 from Gilead. Gilead received an equity stake and is eligible for undisclosed milestones and royalties. Amygdala expects to begin two or three Phase II trials this year of GS-6637 in alcohol and...
21:05 , Feb 16, 2017 |  BC Extra  |  Company News

Amygdala acquires addiction candidate from Gilead

Amygdala Neurosciences Inc. (Palo Alto, Calif.) said it acquired GS-6637 from Gilead Sciences Inc. (NASDAQ:GILD). The company expects to begin clinical trials this year of the candidate to treat cocaine and alcohol use disorders. GS-6637...
07:00 , Sep 25, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Aldehyde dehydrogenase 2 family mitochondrial (ALDH2) Rodent studies suggest stimulating ALDH2 could help treat pain. In a mouse model of inflammation-induced pain, a heterozygous...
00:36 , Aug 26, 2014 |  BC Extra  |  Financial News

Aldea closes $24 million B round

Aldea Pharmaceuticals Inc. (Redwood City, Calif.) closed a $24 million series B round led by new investor RusnanoMedInvest. New investor WuXi PharmaTech Corporate Venture also participated, along with all of Aldea's existing investors, including Canaan...
07:00 , Jun 19, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Cancer Cancer Aldehyde dehydrogenase (ALDH); c-Met proto-oncogene (MET; HGFR); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1) Cell culture and mouse studies suggest ALDH inhibitors could help treat cancer. In human cancer cell lines expressing...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Clinical News

Alnylam, Tekmira preclinical data

In animals, Tekmira's TKM-ALDH2 reduced liver aldehyde dehydrogenase 2 family mitochondrial (ALDH2) protein to undetectable levels (<2%) and increased blood acetaldehyde levels - a biomarker of aldehyde dehydrogenase inhibition - following the introduction of alcohol....
08:00 , Dec 1, 2011 |  BC Innovations  |  Targets & Mechanisms

Taken to heart

A study by Stanford University School of Medicine researchers suggests a mitochondrial enzyme activator called Alda-1 could help decrease the risk of cardiac injury in patients receiving nitroglycerin for cardiac conditions. 1 ALDEA Pharmaceuticals Inc....
08:00 , Nov 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Angina; myocardial infarction (MI); heart failure Aldehyde dehydrogenase 2 family mitochondrial (ALDH2) Rat studies suggest an ALDH2 activator plus nitroglycerin...